Որոնման արդյունքները - Michael Becka
- Ցուցադրվում են 1 - 9 արդյունքները 9
-
1
-
2
-
3
-
4
-
5
-
6
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct <scp>F</scp>actor <scp>X</scp>a inhibitor Dagmar Kubitza, Angelika Roth, Michael Becka, Abir Alatrach, Atef Halabi, Holger Hinrichsen, Wolfgang Mueck
Հրապարակվել է 2013Artigo -
7
Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study Reinhold Kreutz, Pontus B. Persson, Dagmar Kubitza, Karin Thelen, Stefan Heitmeier, Stephan Schwers, Michael Becka, Melanie Hemmrich
Հրապարակվել է 2017Artigo -
8
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Atef Halabi, Haidar Maatouk, Norbert Klause, Volkmar Lufft, Dominic D. Wand, Thomas Philipp, Heike Bruck
Հրապարակվել է 2010Artigo -
9
Serum markers detect the presence of liver fibrosis: A cohort study William Rosenberg, Michael Voelker, Robert Thiel, Michael Becka, Alastair D. Burt, Detlef Schuppan, Stefan G. Hübscher, Tania Roskams, Massimo Pinzani, Michael J.P. Arthur
Հրապարակվել է 2004Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Internal medicine
Medicine
Atrial fibrillation
Pharmacokinetics
Pharmacology
Rivaroxaban
Warfarin
Pharmacodynamics
Pathology
Prothrombin time
Alternative medicine
Area under the curve
Anesthesia
Gastroenterology
Placebo
Adverse effect
Anticoagulant
Antifungal
Apixaban
Atorvastatin
Bioavailability
Biopsy
CYP3A4
Chemistry
Chronic liver disease
Cirrhosis
Clinical trial
Coagulation
Confidence interval
Creatinine